(Q27640076)

17

0 references

Jan Konvalinka

18

0 references

Thomas Klimkait

15

Thomas Klimkait

0 references

Martin Lepšík

Martin Lepsík

3

1 reference

ORCID Public Data File 2021

Jan Weber

Jan Weber

1

1 reference

ORCID Public Data File 2021

Jiří Vondrášek

14

Jirí Vondrásek

0 references

author name string

Jeroen R Mesters

2

0 references

Jana Prejdová

4

0 references

Martin Svec

5

0 references

Jana Sponarová

6

0 references

Petra Mlcochová

7

0 references

Kristina Skalická

8

0 references

Kvido Strísovský

9

0 references

Tána Uhlíková

10

0 references

Milan Soucek

11

0 references

Ladislav Machala

12

0 references

Marie Stanková

13

0 references

Hans Georg Kraeusslich

Journal of Molecular Biology

16

0 references

language of work or name

English

0 references

publication date

6 December 2002

0 references

published in

0 references

volume

324

0 references

issue

4

0 references

page(s)

739-54

0 references

cites work

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Structural mechanisms of HIV drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

On the size of the active site in proteases. I. Papain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Resistance to human immunodeficiency virus type 1 protease inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Development of drug resistance to HIV-1 protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Inhibitors of HIV-1 protease: a major success of structure-assisted drug design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Rational approach to AIDS drug design through structural biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Structural and kinetic analysis of drug resistant mutants of HIV-1 protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

A picomolar inhibitor of resistant strains of human immunodeficiency virus protease identified by a combinatorial approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

SURFNET: a program for visualizing molecular surfaces, cavities, and intermolecular interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

17 The kinetics of reversible tight-binding inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Processing of X-ray diffraction data collected in oscillation mode

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

MOLREP: an Automated Program for Molecular Replacement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

The CCP4 suite: programs for protein crystallography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Refinement of macromolecular structures by the maximum-likelihood method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Conformational flexibility of the catalytic Asp dyad in HIV-1 protease: An ab initio study on the free enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Solvent-accessible surfaces of proteins and nucleic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Statistical potentials for fold assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7

inferred from DOI database lookup

7 January 2021

based on heuristic

An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2836%2802%2901139-7